Zydus Lifesciences Dirección
Dirección controles de criterios 3/4
El CEO de Zydus Lifesciences es Sharvil Patel , nombrado en Apr 2017, tiene una permanencia de 7.58 años. compensación anual total es ₹300.00M, compuesta por 60% salario y 40% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.001% de las acciones de la empresa, por valor de ₹14.10M. La antigüedad media del equipo directivo y de la junta directiva es de 6.5 años y 7.3 años, respectivamente.
Información clave
Sharvil Patel
Chief Executive Officer (CEO)
₹300.0m
Compensación total
| Porcentaje del salario del CEO | 60.0% |
| Permanencia del CEO | 7.6yrs |
| Participación del CEO | 0.001% |
| Permanencia media de la dirección | 6.5yrs |
| Promedio de permanencia en la Junta Directiva | 7.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹43b |
| Jun 30 2024 | n/a | n/a | ₹42b |
| Mar 31 2024 | ₹300m | ₹180m | ₹38b |
| Dec 31 2023 | n/a | n/a | ₹30b |
| Sep 30 2023 | n/a | n/a | ₹28b |
| Jun 30 2023 | n/a | n/a | ₹25b |
| Mar 31 2023 | ₹263m | ₹180m | ₹20b |
| Dec 31 2022 | n/a | n/a | ₹21b |
| Sep 30 2022 | n/a | n/a | ₹20b |
| Jun 30 2022 | n/a | n/a | ₹22b |
| Mar 31 2022 | ₹200m | ₹180m | ₹22b |
| Dec 31 2021 | n/a | n/a | ₹23b |
| Sep 30 2021 | n/a | n/a | ₹23b |
| Jun 30 2021 | n/a | n/a | ₹23b |
| Mar 31 2021 | ₹263m | ₹180m | ₹22b |
| Dec 31 2020 | n/a | n/a | ₹18b |
| Sep 30 2020 | n/a | n/a | ₹17b |
| Jun 30 2020 | n/a | n/a | ₹13b |
| Mar 31 2020 | ₹250m | ₹247m | ₹12b |
| Dec 31 2019 | n/a | n/a | ₹12b |
| Sep 30 2019 | n/a | n/a | ₹14b |
| Jun 30 2019 | n/a | n/a | ₹17b |
| Mar 31 2019 | ₹250m | ₹248m | ₹18b |
| Dec 31 2018 | n/a | n/a | ₹20b |
| Sep 30 2018 | n/a | n/a | ₹20b |
| Jun 30 2018 | n/a | n/a | ₹21b |
| Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Compensación vs. Mercado: La compensación total de Sharvil($USD3.56M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD1.09M).
Compensación vs. Ingresos: La compensación de Sharvil ha sido consistente con los resultados de la empresa en el último año.
CEO
Sharvil Patel (45 yo)
7.6yrs
Permanencia
₹300,000,000
Compensación
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Executive Director | 7.6yrs | ₹300.00m | 0.0015% ₹ 14.1m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 331.8m | |
| President & CEO of America | 1.1yrs | sin datos | sin datos | |
| Chief Financial Officer | no data | ₹54.31m | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Company Secretary & Compliance Officer | 5.8yrs | ₹2.09m | sin datos |
6.5yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de ZYDUSLIFE es experimentado (6.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Executive Director | 27.3yrs | ₹300.00m | 0.0015% ₹ 14.1m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 331.8m | |
| Non-Executive Chairman | 29.5yrs | ₹1.20m | 74.98% ₹ 719.0b | |
| Independent Director | 8.5yrs | ₹4.00m | sin datos | |
| Non-Executive Non-Independent Director | 27.3yrs | ₹4.00m | 0.0012% ₹ 11.1m | |
| Independent Non-Executive Director | 5.9yrs | ₹4.10m | sin datos | |
| Independent Director | 2yrs | ₹3.50m | sin datos | |
| Independent Director | 2yrs | ₹3.50m | sin datos | |
| Independent Director | less than a year | sin datos | 0.00044% ₹ 4.2m |
7.3yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de ZYDUSLIFE se considera experimentada (7.3 años de antigüedad promedio).